Oncology Updates - Key Oncology News
September 2nd Week, 2026
Regulatory Events
🎯 The US FDA granted Accelerated Approval to Bayer’s sevabertinib (HYRNUO; mutant HER2 TKI) for the 1L Tx of HER2-mutant nsq-NSCLC with HER2/ERBB2 tyrosine kinase domain activating mutations (Ref1)
❓ How is sevabertinib positioned in NSCLC Tx landscape?
🎯 The US FDA extended the review period for Exelixis' zanzalintinib (multi-TKI) + Roche's atezolizumab (Tecentriq; anti-PD-L1) NDA for pretreated MSS CRC by 3 months, resulting in a revised PDUFA date of Mar 03, 2027 (Ref2)
❓ How is this delay expected to impact zanzalintinib’s positioning?
Clinical Update
🔬 AstraZeneca’s durvalumab (Imfinzi; anti-PD-L1) + Amgen’s tarlatamab (Imdelltra; DLL3 x CD3 bispecific TCE) regimen demonstrated a statistically and clinically significant OS benefit vs durva alone as 1L maintenance Tx of ES‑SCLC pts not progressed on induction durva + platinum-chemo + etoposide (Ref3)
❓ Which are the key DLL3-targeting assets being developed for ES-SCLC?
🔬 Registrational Ph2 QUINTESSENTIAL trial of Bristol Myers Squibb’ arlocabtagene autoleucel (arlo-cel; auto GPRC5D CAR-T) met its primary endpoint, with regimen showing statistically and clinically significant ORR in ≥4L r/r multiple myeloma (Ref5)
❓ How is arlo-cel positioned within r/r MM developmental landscape?
🔬 In the Ph2/3 HexAgon-HN study, Inhibrx Biosciences, Inc. & Elpiscience Biopharmaceuticals’s INBRX‑106 (anti-OX40) + pembro elicited strong efficacy signals vs pembro mono in 1L PD-L1 CPS ≥20 HNSCC, particularly in the HPV+ subgroup (Ref6)
❓ How do these efficacy outcomes change INBRX‑106 positioning within the oncology developmental landscape?
Setbacks
🛑 The US FDA withdrew Bristol Myers Squibb’ adagrasib’s (Krazati; KRAS inhibitor) 2L KRAS G12C-mutated CRC indication after the confirmatory Ph3 KRYSTAL‑10 study failed to meet survival endpoints (Ref7)
❓ What are the current SOC benchmarks for 2L CRC?
🛑 AstraZeneca's camizestrant (Etcamah; SERD and complete ER antagonist) + hashtag#Pfizer’s palbociclib (CDK4/6 inhibitor) regimen failed to meet the primary PFS endpoint, in 1L ER+/HER2- breast cancer in the Ph3 SERENA-4 trial (Ref8)
❓ How does this failure impact Etcamah’s position in the BC landscape?
To know answers to these questions and for additional insights, write to us at support@oncofocus.com.
🌐 References:
Comments